Yi-Wen Wang

Title: Innovations by Yi-Wen Wang in Targeted Cancer Therapy

Introduction

Yi-Wen Wang is a notable inventor based in Tainan, Taiwan. He has made significant contributions to the field of cancer therapy, particularly in the development of targeted treatments for breast cancer. With a total of 2 patents, his work focuses on innovative approaches to suppress cancer cell proliferation and invasion.

Latest Patents

Yi-Wen Wang's latest patents include a targeted therapy composition aimed at suppressing breast cancer cell proliferation, migration, or invasion. This invention discloses a method for administering a targeted therapy composition to individuals in need. The composition features a type 3 epithelial membrane protein (EMP3) targeted inhibitor, which is crucial for addressing breast cancer cells characterized by the upregulation of EMP3, EGFR, HER2, HER3, and HR, or the downregulation of HER4 gene expression. The targeted oligonucleotide or nuclease is administered to degrade EMP3-coding DNA or mRNA, effectively suppressing breast cancer cell activity.

Another significant patent involves a regulator and a pharmaceutical composition that encompasses this regulator. This invention is designed to modulate the expression of integrins and/or EMP2, making it applicable for treating diseases associated with these proteins.

Career Highlights

Yi-Wen Wang is affiliated with National Cheng-Kung University, where he continues to advance research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.

Collaborations

He collaborates with esteemed colleagues, including Nan-Haw Chow and Yih-Lin Tuan, who contribute to his research endeavors.

Conclusion

Yi-Wen Wang's innovative work in targeted cancer therapy exemplifies the potential of scientific research to transform treatment options for patients. His contributions are paving the way for more effective cancer therapies that can significantly improve patient outcomes.